Cuprina Holdings (Cayman) LTD
CUPRNasdaq
$3.97
↓ -1.0%Jul 17 close · end-of-day
Price
1Y↓ -93.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$81.3M
Enterprise Value
$79.0M
P/E
—
P/S
2095.2
P/B
20.7
EV/EBITDA
—
PEG
—
FCF Yield
-8.8%
Dividend Yield
—
Revenue (TTM)
$38,789.00
Net Income (TTM)
-$3.6M
Free Cash Flow (TTM)
-$7.1M
Gross Margin
-1.3%
Operating Margin
-9680.1%
Net Margin
—
ROE
—
ROIC
-181.5%
Debt / Equity
0.0
Net Cash
$2.3M
Return 1Y
-93.4%
Company profile
We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our principal executive office is in Singapore.
- CEO
- Yong Qi David Quek
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 14
- Website
- cuprina.com
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | $35,522.00 | $38,789.00 |
| Gross profit | — | — | -$2,223.00 | -$501.00 |
| Operating income | — | — | -$1.2M | -$3.8M |
| Net income | — | — | -$1.1M | -$3.6M |
| Diluted EPS | — | — | -$6.38 | -$17.75 |
| Operating cash flow | — | — | -$908,609.00 | -$7.1M |
| Free cash flow | — | — | -$924,697.00 | -$7.1M |
| Gross margin | — | — | -6.3% | -1.3% |
| Operating margin | — | — | -3404.9% | -9680.1% |
| Net margin | — | — | -3229.5% | -9366.7% |
No quarterly data.
Company news
Jun 15, 2026
- 35d agoSector Update: Healthcare Stocks Softer Late Afternoonfinance.yahoo.com
- 35d agoTop Midday Gainersfinance.yahoo.com
- 35d agoSector Update: Healthcare Stocks Softer Monday Afternoonfinance.yahoo.com
- 35d agoWhy Did CUPR Stock Surge Over 150% Today?stocktwits.com
- 35d agoCuprina Receives U.S. FDA 510(k) Clearance for MEDIFLY Maggots — the First U.S. Clearance for a Lucilia cuprina Maggot Debridement Productfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.